{"url_path":"/sec/iccc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 **–**EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/811641/0001437749-26-017045-index.html","accession_number":"0001437749-26-017045","cik":"0000811641","ticker":"ICCC","issuer_name":"IMMUCELL CORP /DE/","edgar_url":"https://www.sec.gov/Archives/edgar/data/811641/0001437749-26-017045-index.html","primary_entity_key":"0000811641","primary_entity_name":"IMMUCELL CORP /DE/"},"word_count":356,"has_tables":true,"body_markdown":"**ITEM 6**–**EXHIBITS**\n\n \n\n \nExhibit 10.1+\n[Employment Agreement between the Company and Timothy C. Fiori dated as of January 27, 2026 (incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K filed February 2, 2026).](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915264.htm)\n\n \nExhibit 10.2+\n[Employment Agreement between the Company and Bobbi Jo Brockmann dated as of January 27, 2026 (incorporated by reference to Exhibit 10.2 of Current Report on Form 8-K filed February 2, 2026).](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915265.htm)\n\n \nExhibit 10.3+\n[Performance-Based Incentive Stock Option Agreement between the Company and Paul Olivier te Boekhorst (incorporated by reference to Exhibit 10.3 of Current Report on Form 8-K filed February 2, 2026).](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915266.htm)\n\n \nExhibit 31.1*\n[Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_908800.htm)\n\n \nExhibit 31.2*\n[Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_908801.htm)\n\n \nExhibit 32.1*\n[Certification of the Chief Financial Officer pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_908802.htm)\n\n \nExhibit 32.2*\n[Certification of the President and Chief Executive Officer pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_908803.htm)\n\n \n101.INS*\nInline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n101.SCH*\nInline XBRL Taxonomy Extension Schema Document.\n\n \n101.CAL*\nInline XBRL Taxonomy Extension Calculation Linkbase Document.\n\n \n101.DEF*\nInline XBRL Taxonomy Extension Definition Linkbase Document.\n\n \n101.LAB*\nInline XBRL Taxonomy Extension Label Linkbase Document.\n\n \n101.PRE*\nInline XBRL Taxonomy Extension Presentation Linkbase Document.\n\n \n104*\nCover Page Interactive Data File-the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n \n \n\n \n+Management contract or compensatory plan or arrangement.\n\n \n*Filed herewith.\n\n20\n\n[Table of Contents](#toc)\n\nImmuCell Corporation\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nImmuCell Corporation\n\n \nRegistrant\n\n \n\n \n\nDate:       May 14, 2026\n\nBy: /s/ Timothy C. Fiori\n\n \n\nTimothy C. Fiori\n\n \n\nChief Financial Officer and\n\n \nPrincipal Financial Officer\n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n \n\n \n\n21"}